DDrare: Database of Drug Development for Rare Diseases

Polaprezinc (DrugBank: Polaprezinc)

2 diseases

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	1
97	Ulcerative colitis	1

96. Crohn disease [ 2,209 clinical trials, 1,276 drugs, (DrugBank: 240 drugs), 166 drug target genes, 210 drug target pathways]

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 2,209 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000005970	2011/07/01	13/07/2011	Investigation on the remission maintaining effect of Polaprezinc in patients with Crohn's disease in remission phase.		Patients with Crohn's disease in remission phase	Polaprezinc administration group: patients has Polaprezinc 150mg/day for xxx months with Crohn's disease maintenance therapy. Polaprezinc non administration group: patients treated with Crohn's disease maintenance therapy only.	Kawasaki Medical School	NULL	Recruiting	20years-old	Not applicable	Male and Female	100	Not selected	Japan

97. Ulcerative colitis [ 2,269 clinical trials, 1,331 drugs, (DrugBank: 241 drugs), 114 drug target genes, 181 drug target pathways]

Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 2,269 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000008967	2009/01/01	24/09/2012	Efficacy of zinc-carnosine chelate compound, Polaprezinc, enemas in patients with ulcerative colitis		Ulcerative Colitis	Polaprezinc group: Polaprezinc enema contained 150 mg of Polaprezinc suspension in tap water (total volume 100 mL) daily for one week Placebo group: 100 mL tap water enema daily for one week	The Jikei University School of MedicineDivision of Gastroenterology and Hepatology	NULL	Complete: follow-up complete	18years-old	Not applicable	Male and Female	30	Not applicable	Japan